| abstract |
An isoniazid dry powder inhalant for treating pulmonary tuberculosis, having high stability, containing an isoniazid micro-powder, and containing or not containing a carrier micro-powder. The particle size of the isoniazid micro-powder is processed to 0.1-10 μm by means of a fluidized bed supersonic jet milling method or a spray drying method. Preferably, an adjuvant such as leucine, mannitol, or phospholipid can be added into the dry powder inhalant to improve the granulation rate of the particles, and an adjuvant such as magnesium stearate, mannitol, leucine, and/or lactose are additionally added to improve the fluidity of the drug and reduce particle agglomeration. The dry powder inhalant is suitable for treating pulmonary tuberculosis patients with liver dysfunction. |